An unexpired patent currently prevents any company from making a generic version of Adasuve (loxapine inhalation powder). The earliest predictable date that a generic version could become available is December 2015, when the patent is set to expire. Although loxapine is sometimes called the "generic name" of Adasuve, it is simply the active ingredient in the medication and not a generic version of it.
Adasuve™ (loxapine inhalation powder) is a prescription medication approved to treat agitation in certain people with schizophrenia or bipolar disorder. It comes as a powder that is inhaled into the mouth using a disposable inhaler.
Adasuve is made by Alexza Pharmaceuticals, Inc. It is currently under the protection of a patent that prevents any generic Adasuve from being manufactured in the United States.
The first patent for Adasuve is set to expire on December 21, 2015. This is the earliest possible date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include things such as lawsuits or other patents for new Adasuve uses. Once the patent expires, several companies may begin manufacturing a generic Adasuve drug.
No -- loxapine is the active ingredient in Adasuve, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.
Loxapine is also available in the form of a capsule as the brand-name drug Loxitane®. Loxitane is approved to treat schizophrenia.